Document is current

Article History

Received: 12 September 2023

Revised: 6 November 2023

Accepted: 1 December 2023

First Online: 12 December 2023

Declarations

:

: All authors, except those mentioned below, declare no conflict of interest. TT reports honoraria from Pfizer, Otsuka, MSD, Chugai, Parma, and Astellas outside the submitted work. SF has received honoraria from Bristol-Myers-Squibb, Astellas, Nippon Shinyaku, Otsuka, Pfizer, Novartis, MSD, Sanofi, Janssen, SymBio, Kyowa Hakko Kirin, AstraZeneca, CSL Behring, Meiji Seika Pharma, AbbVie, Takeda, and Chugai Pharma, and received research funding from Shionogi, Kyowa Hakko Kirin, Chugai Pharma, Otsuka, Asahi-Kasei, and Daiichi Sankyo outside the submitted work. HN reports honoraria from Novartis and Daiichi-Sankyo, scholarships from Daiichi-Sankyo, Celgene, Chugai, Nihon-Shinyaku, Astellas, Asahi Kasei pharma, Takeda, Pfizer, and Eisai outside the submitted work.